July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Real world clinical audit of aflibercept and ranibizumab use in the management of macular oedema secondary to central retinal vein occlusion
Author Affiliations & Notes
  • Mohammed Elatfy
    UCL, London, United Kingdom
    Ophthalmic department, North Middlesex University Hospital, London, United Kingdom
  • Jonathan Than
    Ophthalmic department, North Middlesex University Hospital, London, United Kingdom
  • George Palexas
    Ophthalmic department, North Middlesex University Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships   Mohammed Elatfy, None; Jonathan Than, None; George Palexas, None
  • Footnotes
    Support  NONE
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5440. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mohammed Elatfy, Jonathan Than, George Palexas; Real world clinical audit of aflibercept and ranibizumab use in the management of macular oedema secondary to central retinal vein occlusion. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5440.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Purpose: landmark multi centre studies (COPERNICUS, GALILEO and CRUISE) have demonstrated the efficacy of aflibercept and ranibizumab use for treating macular oedema secondary to central retinal vein occlusion (CRVO) under highly controlled circumstances. This retrospective, observational clinical audit examines and compares aflibercept and ranibizumab treatment outcome to idealized outcomes of the landmark studies.

Methods : Methods: between April 2014 and July 2017, fifty-eight eyes with macular oedema secondary to CRVO were treated with aflibercept as first line interavitreal agent compared to 46 eyes treated with ranibizumab in the ophthalmic department of North Middlesex University Hospital at monthly intervals until maximum visual acuity and OCT parameters were realized. All patients treated in the unit during this period were analyzed retrospectively for the following outcomes: gain 15 or more ETDRS letters of vision, total visual gain, decrease in OCT-measured CRT, proportion achieving dry OCT, progression to neovascularisation, and time to treatment commencement from diagnosis. Data was prospectively collected and compared. An interim analysis is provided herein.

Results : Methods: between April 2014 and July 2017, 58 eyes with macular oedema secondary to CRVO were treated with aflibercept as first line agent compared to 46 eyes treated with ranibizumab in the ophthalmic department of NMUH at monthly intervals until maximum visual acuity and OCT parameters were realized. All patients treated in the unit during this period were analyzed retrospectively for the following outcomes: gain 15 or more ETDRS letters of vision, total visual gain, decrease in OCT-measured central retinal thickness (CRT), proportion achieving dry OCT, progression to neovascularisation, and time to treatment commencement from diagnosis.

Conclusions : Conclusions:
In a real world setting, treatment of macular oedema secondary to CRVO either by aflibercept or ranibizumab compares favourably to the landmark clinical trials with idealized circumstances. Although visual acuity parameters did not improve to the same degree as in the clinical trials, anatomical parameters did.The audit shows visual acuity outcomes and resolution of macular oedema are better in patients who started treatment within six months from diagnosis compared to those who had delayed treatment.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×